Certara, Inc. (NASDAQ:CERT) Receives $15.67 Consensus Price Target from Analysts

Certara, Inc. (NASDAQ:CERT) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $15.71.

A number of analysts have commented on CERT shares. Robert W. Baird upped their price target on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. KeyCorp increased their target price on Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. JMP Securities restated a “market perform” rating on shares of Certara in a report on Tuesday, May 6th. Finally, Morgan Stanley started coverage on Certara in a report on Thursday. They set an “equal weight” rating and a $16.00 price target for the company.

Certara Trading Down 1.4%

Certara stock opened at $11.33 on Wednesday. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. The business’s fifty day simple moving average is $11.65 and its two-hundred day simple moving average is $11.85. Certara has a 12 month low of $8.64 and a 12 month high of $16.93. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -566.50 and a beta of 1.43.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. The business had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 earnings per share. As a group, equities analysts predict that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

Several institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc lifted its stake in shares of Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after acquiring an additional 1,866 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Certara during the 1st quarter worth $31,000. Wells Fargo & Company MN increased its holdings in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the period. AlphaQuest LLC purchased a new position in Certara during the 1st quarter worth $39,000. Finally, Johnson Financial Group Inc. purchased a new position in Certara during the 4th quarter worth $47,000. 73.96% of the stock is owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.